TLR4 and neurodegenerative disease: Several studies have reported that drugs that reduce proinflammatory cytokine levels in vitro and in vivo via TLR4-dependent signaling pathways hold potential for treating neuroinflammation-linked neurodegenerative diseases [20, 21, 36, 37].